<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780127</url>
  </required_header>
  <id_info>
    <org_study_id>ZX008-1800</org_study_id>
    <nct_id>NCT03780127</nct_id>
  </id_info>
  <brief_title>ZX008 Expanded Access Protocol</brief_title>
  <official_title>ZX008 Expanded Access Protocol - Dravet Syndrome Treatment Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zogenix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zogenix, Inc.</source>
  <brief_summary>
    <textblock>
      The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who&#xD;
      do not qualify for participation in one of the ongoing ZX008 clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment plan consists of an up to 24-month Treatment Period. Access is via application&#xD;
      by your health care provider and available at one of the Expanded Access treatment centers.&#xD;
      The dose of ZX008 for the duration of the Treatment Period will range from 0.2 mg/kg/day to a&#xD;
      maximum of 0.8 mg/kg/day, not to exceed a total daily dose of 30 mg/day; for patients&#xD;
      concurrently being prescribed stiripentol, the maximum will be 0.5mg/kg/day, not to exceed a&#xD;
      total daily dose of 20 mg/day.&#xD;
&#xD;
      The fenfluramine US Expanded Access Program (US EAP) is available to full-time US Residents&#xD;
      only.&#xD;
&#xD;
      Participation in the US EAP is limited to patients currently residing in the US. Residency in&#xD;
      the US must be for the duration of participation in the US EAP. Drug may not be shipped&#xD;
      outside the US.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Dravet Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenfluramine Hydrochloride</intervention_name>
    <description>ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.</description>
    <other_name>ZX008</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is male or female, age 2 years and older, inclusive as of Study Day 1.&#xD;
&#xD;
          -  Patient is diagnosed with Dravet syndrome.&#xD;
&#xD;
          -  Patient is experiencing convulsive seizures which are not controlled by current AEDs.&#xD;
&#xD;
          -  Patient is receiving at least one AED and will remain on at least one AED for the&#xD;
             duration of treatment.&#xD;
&#xD;
          -  Patient has been approved for inclusion by Zogenix.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient requires or starts using an unacceptable or contraindicated concomitant&#xD;
             medication.&#xD;
&#xD;
          -  Patient has valvulopathy.&#xD;
&#xD;
          -  Patient is at risk for pulmonary hypertension.&#xD;
&#xD;
          -  Patient exclusion will be at the sole discretion of the Sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsies, Myoclonic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenfluramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

